格隆汇1月27日丨新光光电(688011.SH)公布，经财务部门初步测算，预计2025年公司实现营业收入约 11,600.00万元，预计扣除与主营业务无关的业务收入和不具有商业实质的收入后的营业收入约11,300.00 万元。实现归属于上市公司股东的净利润将出现亏损，预计实现归属于上市公司股东的净利润 为-3,500.00万元到-4,300.00万元，减亏3,295.84万元至2,495.84万元。预计归属于上市公司股东的扣除非 经常性损益后的净利润为-5,385.00万元到-6,185.00万元，减亏2,851.57万元至2,051.57万元。 公司收入减少主要原因：军品产品，部分研发产品已交付至客户，但目前正进行系统的联调、测试，未 达到验收条件；某型号批产产品未能在报告期内完成交付；民品产品，报告期内合同订单同比减少。由 于营业收入同比减少，导致本期出现亏损。报告期内，公司期间费用同比下降约24%，本期收到的退税 款及与经营相关的政府补助同比增长约102%。以上综合因素导致公司报告期收入下降约32%情况下归 母净利润减亏3,295.84万元至2,495.84万元。 ...

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]